Ventilator Associated Pneumonia (VAP) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) – Pipeline Review, H1 2017’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)

The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects

The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Shionogi & Co Ltd

TGV-Inhalonix Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ventilator Associated Pneumonia (VAP) - Overview

Ventilator Associated Pneumonia (VAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Shionogi & Co Ltd

TGV-Inhalonix Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Ventilator Associated Pneumonia (VAP) - Drug Profiles

(amikacin sulfate + fosfomycin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam sodium + aztreonam lysine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cilastatin sodium + imipenem + relebactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem+ vaborbactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AA-139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aerucin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amikacin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbekacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefepime + zidebactam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eravacycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin tromethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iclaprim mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Panaecin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

panobacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plazomicin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-7001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qn-2251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvratoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tedizolid phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telavancin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viritron VDX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ventilator Associated Pneumonia (VAP) - Dormant Projects

Ventilator Associated Pneumonia (VAP) - Discontinued Products

Ventilator Associated Pneumonia (VAP) - Product Development Milestones

Featured News & Press Releases

Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA

May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference

Feb 26, 2016: Pendopharm Launches Vibativ In Canada

Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets

Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia

Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured

Sep 10, 2015: Theravance Biopharma Announces FDA Acceptance of sNDA to Expand VIBATIV Labeling

Jul 23, 2015: Theravance Biopharma Announces Health Canada Approval for VIBATIV(telavancin) for Treatment of HAP/VAP Caused by Gram-Positive Bacteria, Including MRSA

Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia

May 29, 2015: Meiji announces that FDA Grants QIDP and Fast Track Designation to ME1100

Feb 10, 2015: Theravance Biopharma Initiates Patient Registry Study for VIBATIV (telavancin)

Jul 26, 2013: Meiji Initiates Phase 1 Clinical Trial of Arbekacin Inhalation Solution (ME1100) in the U.S.

Jun 21, 2013: Theravance Gets FDA Approval For Vibativ For Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Achaogen Inc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Adenium Biotech ApS, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by AstraZeneca Plc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Bayer AG, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Cardeas Pharma Corp, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Destiny Pharma Ltd, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Lakewood-Amedex Inc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by MedImmune LLC, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Meiji Seika Pharma Co Ltd, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Merck & Co Inc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Motif Bio Plc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Nabriva Therapeutics AG, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Polyphor Ltd, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Shionogi & Co Ltd, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by TGV-Inhalonix Inc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by The Medicines Company, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Theravance Biopharma Inc, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Wockhardt Ltd, H1 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Zavante Therapeutics Inc, H1 2017

Ventilator Associated Pneumonia (VAP) – Dormant Projects, H1 2017

Ventilator Associated Pneumonia (VAP) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports